Ellegood, J
Anagnostou, E
Babineau, B A
Crawley, J N
Lin, L
Genestine, M
DiCicco-Bloom, E
Lai, J K Y
Foster, J A
Peñagarikano, O
Geschwind, D H
Pacey, L K
Hampson, D R
Laliberté, C L
Mills, A A
Tam, E
Osborne, L R
Kouser, M
Espinosa-Becerra, F
Xuan, Z
Powell, C M
Raznahan, A
Robins, D M
Nakai, N
Nakatani, J
Takumi, T
van Eede, M C
Kerr, T M
Muller, C
Blakely, R D
Veenstra-VanderWeele, J
Henkelman, R M
Lerch, J P
Article History
Received: 19 March 2014
Revised: 14 July 2014
Accepted: 15 July 2014
First Online: 9 September 2014
Competing interests
: EA has received consultation fees from Novartis and Seaside therapeutics, and has an unrestricted grant from Sanofi Canada. JV-VW receives research funding from Seaside Therapeutics, Novartis, Roche Pharmaceuticals, Forest, Sunovion and SynapDx and sits on the advisory board for Novartis and Roche Pharmaceuticals. The remaining authors declare no conflict of interest.